STCube Reveals World Lung Cancer Conference Research Abstract... "Suggesting Treatment Directions for Small Cell Lung Cancer"

STCube has revealed research results related to the development of a small cell lung cancer (SCLC) treatment ahead of its participation in the ‘2023 World Conference on Lung Cancer (2023 WCLC)’ to be held in Singapore from September 9 to 12 (local time) next month.

On the 17th, STCube announced that the research abstract for Nelmastobat (hSTC810) has been published on the WCLC website.

At this conference, STCube will focus on presenting the expression characteristics of BTN1A1 (the immune checkpoint protein targeted by Nelmastobat) in small cell lung cancer.

In phase 1 clinical trials, STCube verified the safety of Nelmastobat and revealed a strong correlation between the expression of BTN1A1 and certain immune cells. BTN1A1 showed particularly high expression rates in small cell lung cancer, which is known for low PD-L1 expression and poor response to most immune checkpoint inhibitors.

In the case of small cell lung cancer, progression-free survival (PFS) was maintained at about 8 months or more with stable disease (SD) in phase 1 clinical trials. Among them, one small cell lung cancer patient has maintained stable disease (SD) with tumor size reduction without any adverse reactions to date.

Accordingly, STCube is currently preparing follow-up clinical trials targeting small cell lung cancer. On the 4th, the company submitted an Investigational New Drug (IND) application for phase 1b/2 clinical trials to the Ministry of Food and Drug Safety to verify the efficacy of Nelmastobat. Multiple major multinational hospitals are actively participating in research to develop combination therapies for small cell lung cancer.

Investigator-initiated clinical trials are also expected to proceed actively. The indications will be expanded to colorectal cancer, bladder cancer, and non-small cell lung cancer, and investigator-initiated trials focusing on the efficacy of Nelmastobat as a first-line treatment for small cell lung cancer are currently under discussion. The company also plans to apply for orphan drug designation aiming for rapid product approval.

An STCube representative stated, “Nelmastobat is expected to show high efficacy when used in combination with chemotherapy or PD-L1 immune checkpoint inhibitors,” adding, “We will secure competitiveness to enter rapid commercialization through follow-up clinical trials, investigator-initiated trials, and orphan drug designation.”

Small cell lung cancer is a rare disease accounting for 15% of all lung cancers. According to data from the Korea Institute of Science and Technology Information, the small cell lung cancer treatment market is a high-growth sector expected to grow at an average annual rate of nearly 20%.

This content was produced with the assistance of AI translation services.